Sökresultat - Portal för medicinska datamodeller (MDM-portal)

dbGaP phs000980 PD-1 Blockade in Non-Small Cell Lung Cancer - Eligibility

- 2023-11-18 - 5 Formulär, 1 Item-grupp, 1 Dataelement, 1 Språk

Item-grupp: IG.elig

Principal Investigator: Timothy Chan, MD, PhD, Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA MeSH: Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000980 Patients with non-small cell lung cancer were treated with pembrolizumab. Their tumors and matched normal blood were sequenced.

Carcinoma, Non-Small-Cell Lung

Lung Cancer NCT00499330 On-Study - CALGB: 140503 On-Study Form - 2537927v1.0 - CALGB: 140503 On-Study Form

- 2015-01-09 - 1 Formulär, 5 Item-grupper, 33 Dataelement, 1 Språk

Item-grupper: Header, Header, Pulmonary Function Tests, Smoking Status, Footer

CALGB: 140503 On-Study Form Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=218D3F85-A366-6278-E044-0003BA3F9857

Lung Cancer NCT01336894 On-Study - ACOSOG-Z4099 On-Study Form - 3181084v1.0 - ACOSOG-Z4099 On-Study Form

- 2015-01-09 - 1 Formulär, 9 Item-grupper, 50 Dataelement, 1 Språk

Item-grupper: Header Module, Visit, Histologic Information, Patient Status Information, Baseline PET Findings, Surgery Risk Factors, Clinical Stage, Pre-treatment PFT's, Smoking Status

ACOSOG-Z4099 On-Study Form Surgery With or Without Internal Radiation Therapy Compared With Stereotactic Body Radiation Therapy in Treating Patients With High-Risk Stage I Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=990BA4F9-52BF-85C0-E040-BB89AD433BEA

Lung Cancer NCT01041781 Registration - CALGB-30801 Registration Worksheet Form - 2891095v1.0 - CALGB-30801 Registration Worksheet Form

- 2021-09-20 - 1 Formulär, 9 Item-grupper, 36 Dataelement, 1 Språk

Item-grupper: Header Module, Protocol Administration, Patient Demographics/Pre-Treatment Characteristics1, Patient Demographics/Pre-Treatment Characteristics2, Patient Demographics/Pre-Treatment Characteristics3, Certification Of Eligibility, Protocol Design, Companion Study, Registration Information

CALGB-30801 Registration Worksheet Form Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AF26CA3-DB68-EEE0-E040-BB89AD436D54

On-Study - Phase II Lung Cancer - NSCLC Advanced On-Study Form - 2398811v1.0 - Phase II Lung Cancer - NSCLC Advanced On-Study Form

- 2021-09-20 - 1 Formulär, 8 Item-grupper, 55 Dataelement, 1 Språk

Item-grupper: CRF Header, Pre-Treatment Characteristics , Disease Description NSCLC ADVANCED, Prior Treatment - NSCLC Advanced, Prior Systemic Therapy NSCLC Advanced, Surgical Procedure Description , Prior Radiation Therapy - NSCLC Advanced, Comments

Phase II Consortium - Phase II Lung Cancer - NSCLC Advanced On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=FF7A9F25-B26C-5224-E034-0003BA3F9857

Lung Cancer NCT01107626 Eligibility - E5508 Registration Worksheet (step 2) - 3078042v1.0 - E5508 Registration Worksheet (step 2)

- 2021-09-17 - 1 Formulär, 3 Item-grupper, 19 Dataelement, 1 Språk

Item-grupper: Eligibility, Demographic Data Required For Patient Registration, I have reviewed the above data and agree the date are accurate and correct

E5508 Registration Worksheet (step 2) Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=8528E45F-A327-F490-E040-BB89AD4356FC

Eligibility Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer NCT00590902

- 2016-06-15 - 1 Formulär, 2 Item-grupper, 17 Dataelement, 1 Språk

Item-grupper: Inclusion Criteria, Exclusion Criteria

Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00590902

Lung Cancer NCT01041781 On-Study - CALGB: 30801 Respiratory On-Study Form - 2891327v1.0 - CALGB: 30801 Respiratory On-Study Form

- 2015-01-09 - 1 Formulär, 7 Item-grupper, 43 Dataelement, 1 Språk

Item-grupper: Header Module, Disease Status, Current Clinical Data, Prior Therapy, Lab Data at Protocol Entry, TNM Staging, Footer Module

CALGB: 30801 Respiratory On-Study Form Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6AF26CA3-DD74-EEE0-E040-BB89AD436D54

Lung Cancer NCT00693992 On-Study - CALGB: 30607 Respiratory On-Study Form - 2663922v1.0 - CALGB: 30607 Respiratory On-Study Form

- 2015-01-09 - 1 Formulär, 7 Item-grupper, 38 Dataelement, 1 Språk

Item-grupper: Header, Disease Status, Current Clinical Data, Prior Therapy, Lab Data at Protocol Entry, TNM Staging, Footer

CALGB: 30607 Respiratory On-Study Form Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=3525C2EE-8272-3D39-E044-0003BA3F9857

Lung Cancer NCT00324805 Demographic - ECOG-E1505 Baseline Smoking Survey - 2438323v1.0 - ECOG-E1505 Baseline Smoking Survey

- 2015-01-09 - 1 Formulär, 4 Item-grupper, 32 Dataelement, 1 Språk

Item-grupper: Header module, Smoking history and status, Nic Alert Test Result, Investigator signature

ECOG-E1505 Baseline Smoking Survey Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=080E30C9-4544-68FF-E044-0003BA3F9857

Lung Cancer NCT00946712 Pre-Study - Southwest Oncology Group S0819 Prestudy Form - 2863901v1.0 - Southwest Oncology Group S0819 Prestudy Form

- 2021-09-20 - 1 Formulär, 8 Item-grupper, 72 Dataelement, 1 Språk

Item-grupper: Header Module, PATIENT AND DISEASE DESCRIPTION, PATIENT AND DISEASE DESCRIPTION1, LABORATORY VALUES, LABORATORY VALUES1, ADDITIONAL PRESTUDY DATA, PRIOR TREATMENT RELATED TO THIS CANCER, Comments

Southwest Oncology Group S0819 Prestudy Form Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=684FE956-5AAF-A7DA-E040-BB89AD432A2B

Safety and efficacy of topotecan in patients with extensive-disease small-cell lung cancer (104864/410) - Module 2 - Laboratory Tests - Haematology; Blood Chemistry; Urinalysis

- 2021-04-28 - 1 Formulär, 4 Item-grupper, 21 Dataelement, 1 Språk

Item-grupper: Administrative, Laboratory Tests - Haematology, Laboratory Tests - Blood Chemistry, Laboratory Tests - Urinalysis

Study ID: 104864/410 Clinical Study ID: 104864/410 Study Title: A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Study Indication: Lung Cancer

Nyckelord

Innehållsförteckning

Valda datamodeller